Bone quality and osteoporosis therapy;Qualidade óssea e tratamento da osteoporose

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 186-199

  Martin, Regina Matsunaga ^a   Correa, Pedro Henrique S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone quality; Fracture; Osteoporosis; Strength; Treatment; Turnover

Indexed keywords

EID: 77952711933     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000200015     Document Type: Review

References (65)

1. Christiansen C. Osteoporosis: diagnosis and management today and tomorrow. Bone. 1995;17(5 Suppl):513S-6S.
2. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929-36.
3. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20(10):1813-9.
4. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112(4):281-9.
5. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide- treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21(11):1785-90.
6. Chesnut CH, 3rd, Rosen CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res. 2001;16(12):2163-72.
7. Watts NB. Bone quality: getting closer to a definition. J Bone Miner Res. 2002;17(7):1148-50.
8. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005;27(1):1-11.
9. Link TM, Majumdar S, Augat P, Lin JC, Newitt D, Lu Y, et al. In vivo high resolution MRI of the calcaneus: differences in trabecular structure in osteoporosis patients. J Bone Miner Res. 1998;13(7):1175-82.
10. Chesnut CH, 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005;20(9):1548-61.
11. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int. 2008;19(3):339-48.
12. Laurent Benhamou C. Bone ultrastructure: evolution during osteoporosis and aging. Osteoporos Int. 2009;20(6):1085-7.
13. Leeming DJ, Henriksen K, Byrjalsen I, Qvist P, Madsen SH, Garnero P, et al. Is bone quality associated with collagen age? Osteoporos Int. 2009;20(9):1461-70.
14. Riggs BL, O'Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res. 1994;9(2):265-75.
15. Ruppel ME, Burr DB, Miller LM. Chemical makeup of microdamaged bone differs from undamaged bone. Bone. 2006;39(2):318-24.
16. Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12(1):6-15.
17. Chapurlat RD, Delmas PD. Bone microdamage: a clinical perspective. Osteoporos Int. 2009;20(8):1299-308.
18. Sunyecz J. Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging. 2008;3(4):611-27.
19. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27(5):687-94.
20. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39(2):345-52.
21. Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. 2006;21(7):1106-12.
22. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008;23(1):6-16.
23. Ebeling PR, Burr DB. Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res. 2008;23(1):2-5.
24. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28(5):524-31.
25. Allen MR, Iwata K, Sato M, Burr DB. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone. 2006;39(5):1130-5.
26. Allen MR, Burr DB. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. Bonekey Osteovision. 2007;4(2):49-60.
27. Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int. 2008;19(9):1343-54.
28. Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19(3):329-37.
29. Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006;17(7):986-95.
30. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman AB, et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum. 2006;36(1):10-21.
31. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study. Bone. 2009 Nov 10.
32. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007;22(8):1173 80.
33. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005;20(7):1244-53.
34. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21(6):855-64.
35. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11):1932-41.
36. Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res. 2002;17(10):1741-3.
37. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(3):539-43.
38. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001;16(1):157-65.
39. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004;19(4):623-9.
40. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003;88(3):1150-6.
41. Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan SL, Rosen C, et al. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res. 2008;23(9):1442-8
42. Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab. 2005;90(8):4644-9.
43. Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009 May 19.
44. Reginster JY, Bruyere O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059-64.
45. Cortet B. Strontium ranelate: new perspectives for the management of osteoporosis. Rheumatology (Oxf). 2009;48 Suppl 4:iv1-2.
46. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92(8):3076 81.
47. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004;19(12):2012-20.
48. Ammann P. Strontium ranelate: a physiological approach for an improved bone quality. Bone. 2006;38(2 Suppl 1):15-8.
49. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23(2):215-22.
50. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872-81.
51. Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Fox S, Chow J. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab. 2001;86(1):289-95.
52. Vedi S, Bell KL, Loveridge N, Garrahan N, Purdie DW, Compston JE. The effects of hormone replacement therapy on cortical bone in postmenopausal women. A histomorphometric study. Bone. 2003;33(3):330-4.
53. Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res. 2003;18(6):955-9.
54. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-45.
55. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17(1):1-10.
56. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003;14(10):814-22.
57. Brennan TC, Rizzoli R, Ammann P. Selective modification of bone quality by PTH, pamidronate, or raloxifene. J Bone Miner Res. 2009;24(5):800-8.
58. Boivin G, Lips P, Ott SM, Harper KD, Sarkar S, Pinette KV, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab. 2003;88(9):4199-205.
59. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(3):985-92.
60. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23(4):540-51.
61. Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267-76.
62. Licata AA. Clinical perspectives on bone quality in osteoporosis: effects of drug therapy. Drugs Aging. 2007;24(7):529-35.
63. Bouxsein ML. Determinants of skeletal fragility. Best Pract Res Clin Rheumatol. 2005;19(6):897-911.
64. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab. 2008;26(1):1-8.
65. Hernandez CJ, Keaveny TM. A biomechanical perspective on bone quality. Bone. 2006;39(6):1173-81.